Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation Dose of Oral Tc99m-Heparin
NCT04069429Phase 1Completed
- Sponsor
- University of Utah
- Start
- Jul 2016
- Primary completion
- Sep 2020
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of technetium Tc-99m heparin in eosinophilic esophagitis (EoE) (2 arms), sponsored by University of Utah. Primary endpoints: Biodistribution of Tc99m-heparin and Calculation of organ doses. Started Jul 2016; status: completed.
02
Drugs
technetium Tc-99m heparin
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT04069429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04069429.